Efficacy of anlotinib combined with intensity-modulated radiotherapy in the treatment of inoperable non-small cell lung cancer patients
Objective To investigate the efficacy of anlotinib combined with intensity-modulated radiotherapy(IMRT)in the treatment of inoperable non-small cell lung cancer(NSCLC)patients.Method A total of 102 patients with inoperable NSCLC were divided into control group and study group according to different treatment methods,with 51 cases in each group.Patients in the control group were treated with IMRT,and patients in the study group were treated with anlotinib combined with IMRT.Followed up for 18 months,the clinical efficacy,overall survival rate,progression-free survival(PFS)and overall survival(OS)of the two groups were compared,the tumor-specific survival rates of pa-tients with different pathological type in control group and study group were also compared.Result The objective re-sponse rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).At 6,12 and 18 months after treatment,the overall survival rates of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).At 6,12 and 18 months after treatment,there were no significant differences in tumor-specific survival rates of patients with different pathological type in the control group and the study group(P>0.05).The PFS and OS in the study group were significantly longer than those in the con-trol group,and the differences were statistically significant(P<0.01).Conclusion Anlotinib combined with IMRT in the treatement of patients with inoperable NSCLC can improve clinical efficacy and overall survival rate,and prolong pa-tients'PFS and OS.
NETL
NSTL
万方数据
